Unlocking Hope: Breakthroughs in ALK-Positive Cancer Research for All Ages
The spectrum of ALK-positive cancer knows no age limits. Meet the faces of courage: the ordinary individuals with the ALK-positive mutation. This mutation, notorious for lung cancer in adults, defies the stereotype. At just 52 years old, these fighters, who are usually non-smokers, shatter expectations. Yet, it doesn’t stop there – the youngest warriors, too, bear the burden of ALK-positive mutations. While a handful of kids battle ALK-positive lung cancer, an even greater number grapple with foes like lymphoma, sarcoma, and brain cancer, all stemming from the ALK-positive mutation.
In the realm of medical breakthroughs, a beacon of hope is emerging. The once-overlooked possibility of the ALK-positive mutation in childhood cancers has sparked new investigations. Pioneering strides are being taken as ALK inhibitor medications, originally designed for adults, are now cautiously tested in the youngest patients. A glimpse into the future reveals a promising ray of light – early outcomes from the use of lorlatinib in treating pediatric neuroblastoma brain cancer are promising.
Within the heart of ALK Positive, a sanctuary of information and support thrives. Our extensive compilation of ongoing ALK clinical trials serves as a resource for those with ALK-positive cancers, including trials for those in our pediatric community. The ALK Positive Facebook support group extends a hand to parents grappling with the agonizing reality of pediatric ALK-positive cancers. Together, we share the uncharted territories of ALK inhibitor medications, driven by the knowledge that our collective experience is an invaluable asset in the realm of pediatric oncology.
Dive into a world of innovation, advocacy, and unity. Explore the latest in ALK-positive cancer clinical trials – a realm of hope not confined by age. To be part of this groundbreaking journey, discover more at Clinical Trials Currently Recruiting for ALK-positive Cancers. Uniting science, compassion, and determination, we’re rewriting the narrative of ALK-positive cancers for every generation.
ALK Positive, is seeking more information about the experiences of those diagnosed with ALK-positive lung cancer. They have created a longitudinal survey called the “ALK Life Study” to assist ALK researchers, that has many points of interest, including the experiences of those who have participated in clinical trials. The survey is confidential and approved by the University of Washington research governing body. To complete the survey, please click here: ALK-positive Longitudinal Survey
General Information About Clinical Trials
As of August 2023, there are at least 50 clinical trials that are recruiting specifically for people with ALK-positive lung cancer. Many of these trials have multiple sites worldwide. It is difficult for any oncologist to be aware of all the trials available. You can advocate for yourself and find a clinical trial that may be a good fit for you at any juncture in treatment.
*The ALK Positive Clinical Trials Spreadsheet was developed by the ALK Positive Medical Committee. The database is updated monthly. Disclaimer: these trials have been consolidated by volunteers and should not be considered exhaustive. Listing of these trials is not an endorsement, and ALK Positive does not recommend one trial over another. Please talk with your doctor about these or any trials you are interested in.
By Ellee Urban with assistance from Chatbot GPT.